Target intelligence / Profile preview

HIV-1 Gag, Pol, Env, Tat, Rev, and Vpu proteins (Gag/Pol/Env/Tat/Rev/Vpu)

Target
Gag/Pol/Env/Tat/Rev/Vpu
Molecular classification
Gag: structural protein, Pol: enzyme (polymerase, protease, integrase, reverse transcriptase), Env: viral envelope glycoprotein, Tat: transcription factor/regulatory protein, Rev: RNA-binding regulatory protein, Vpu: membrane protein (ion channel/viroporin, accessory protein)
01

Overview

The HIV-1 Gag, Pol, Env, Tat, Rev, and Vpu proteins are essential products encoded by the HIV-1 genome, collectively performing key structural, enzymatic, transcriptional, regulatory, and accessory functions required for HIV replication and pathogenesis[5][2][4]. - Gag is the structural polyprotein essential for viral assembly, budding, and release, forming the matrix, capsid, and nucleocapsid[2][5]. - Pol encodes viral enzymes required for replication: reverse transcriptase, integrase, and protease[5]. - Env forms the viral envelope glycoproteins responsible for binding to and entering host cells via CD4 and co-receptors[5]. - Tat is a regulatory protein that greatly increases the efficiency of viral RNA transcription[5]. - Rev is another regulatory protein that facilitates the export of unspliced and singly-spliced viral RNAs from the nucleus to the cytoplasm, thus enabling expression of structural proteins[6][5]. - Vpu is an accessory membrane protein that enhances virion release, antagonizes host restriction factors (like tetherin/BST2), and promotes CD4 degradation[4][7][3]. These proteins are all critical to the HIV-1 life cycle and, as such, are frequent or current targets of antiretroviral drugs, although not all are directly targeted by current clinical therapies. The diversity of function among these proteins, as well as rapid viral evolution, presents significant challenges for therapeutic targeting[5][2][4].

Other names
Gag: group-specific antigenPol: polymeraseEnv: envelope proteinTat: trans-activator of transcriptionRev: regulator of virion expressionVpu: viral protein U
02

Mechanism of action

Inhibition of viral reverse transcription, protease activity, or integration (Pol inhibitors) Blocking viral entry/fusion (Env inhibitors; some experimental Gag inhibitors) Disruption of assembly, budding, or release (potential targets for Gag, Vpu)

03

Biological functions

Viral assembly and morphogenesis (Gag)Viral genome replication—reverse transcription, integration, proteolysis (Pol)Viral attachment and entry via CD4/co-receptors (Env)Transcriptional activation of viral genome (Tat)Regulation of RNA export from nucleus and RNA packaging (Rev)Facilitation of virion release, downregulation of CD4, antagonism of host restriction factors (Vpu)
04

Disease associations

Infection (primary role: HIV-1/AIDS)
05

Safety considerations

Drug resistance due to high mutation rates in Pol (reverse transcriptase, protease, integrase)Toxicity from off-target drug effects, immune reconstitution syndromeThe multifaceted roles and redundancy in HIV proteins can limit monotherapy efficacy
06

Interacting drugs

Reverse transcriptase inhibitors (e.g., zidovudine, efavirenz) target Pol

4 more in the full profile.

07

Biomarkers

Detection of viral proteins (p24 antigen, a Gag product, is a diagnostic HIV biomarker)Monitoring of HIV RNA or protein expression for therapeutic responseSpecific mutations in Pol (reverse transcriptase/protease/integrase genes) for drug resistance testing

Beyond the preview

Go deeper on HIV-1 Gag, Pol, Env, Tat, Rev, and Vpu proteins (Gag/Pol/Env/Tat/Rev/Vpu).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on HIV-1 Gag, Pol, Env, Tat, Rev, and Vpu proteins (Gag/Pol/Env/Tat/Rev/Vpu).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call